Skip to content
Screener
Immucell logo

Immucell

ICCC

ImmuCell Corporation is an animal health biologics company specializing in the development and manufacture of products that improve the health and survivability of neonatal dairy and beef calves.

Market cap
$92.82M+67.4%

Earnings

Next report

Date not yet announced

Competitors

Profile

ImmuCell Corporation is an animal health biologics company specializing in the development and manufacture of products that improve the health and survivability of neonatal dairy and beef calves. The company's core value proposition centers on providing immediate passive immunity against calf scours, a leading cause of pre-weaning mortality, through proprietary antibody-based solutions. By utilizing hyperimmunized bovine colostrum, the company offers a science-based alternative to traditional maternal vaccines and nutritional supplements.

Competitive position

ImmuCell is a premium-priced market leader in the calf-level antibody segment, offering the only USDA-licensed orally delivered scours preventatives with guaranteed antibody doses.

GeographiesUnited States, Canada, International
Customer segmentsLivestock Producers, Dairy Farmers, Veterinary Services
Business modelManufacturing, Direct Sales, Distributor-led Distribution
SuppliersBovine colostrum sourcing, Vaccine components, Contract manufacturing for specific formats, Specialized packaging materials
CustomersNational animal health distributors, Regional animal health distributors, Veterinary clinics, Fleet stores, Direct-to-farm sales
Listed1987
Employees80.0
CEOF. Olivier Te Boekhorst
FilingsSEC EDGAR

FAQ

What is Immucell's market cap?
Immucell (ICCC) has a market capitalization of $92.8M and trades on NASDAQ.
Who are Immucell's competitors?
Immucell's key competitors include Elanco Animal Health, Zoetis, Merck & Co., and others. These companies compete in similar markets and product categories.
Where is Immucell headquartered?
Immucell is headquartered in United States of America and employs approximately 80 people. It has been publicly traded since 1987.